My previous column discussed the high cost of researching and developing a new pharmaceutical compound. I noted that the latest estimate, by the Tufts Center for the Study of Drug Development, is “controversial”, and promised to address the controversy. Well, here goes.
Read the entire column at Forbes.
Research and commentary from a former senior executive in the U.S. Department of Health & Human Services
No comments:
Post a Comment